[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinsons-disease-pd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinsons-disease-pd":654},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,64,0,25,[9,55,87,108,132,157,183,206,224,254,273,302,329,350,377,398,428,449,473,500,527,549,577,605,634],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100053577",false,"NCT07697664","Moving Yourself in Space and Time: MYSTIC","Moving Yourself in Space and Time Identifying Spatial and Temporal Components of Complex Rhythmic Movement Training for People With Parkinson's Disease and Cognitive Impairment","MYSTIC","Inclusion Criteria for Young adults and adults with normal cognition (NC):\n\n* 18 to 35 Years old\n* Montreal Cognitive Assessment (MoCA) score of 26 to 30\n\nInclusion Criteria for Older Adults:\n\n* 50 to 79 with or without MCI\n* 50 to 79 years old with Parkinson's disease (PD), who do NOT have impaired decision-making capacity\n* Participants who achieve less than 150 minutes moderate or 75 minutes vigorous aerobic activity per week (as per the US Department of Health and Human Services (HHS)),\n\nExclusion Criteria for all groups:\n\n* Acute medical illness requiring hospitalization;\n* Uncontrolled congestive heart failure;\n* History of stroke in the past three years;\n* Inability to perform study procedures;\n* Medical or physical conditions that would preclude participation (e.g., severe arthritis or mobility problems, uncontrolled hypertension or diabetes, renal failure, history of angina with activity);\n* On medications that could adversely affect cognition, e.g., antipsychotics, opioids, stimulants, chemotherapy, and neurologic prescriptions to treat Multiple Sclerosis. When applicable, enrollment will be delayed until dosages are stable on e.g., Aricept, Namenda, anticholinesterase inhibitors, for at least 3 months\n* Psychotic disorders\n* Confounding neurologic conditions \\[e.g., active central nervous system (CNS) opportunistic infections, seizure disorders, head injury with loss of consciousness \\>30 minutes, intracranial neoplasms, stroke with neurological or neuropsychiatric sequelae\\]\n* Substance Use Disorder, Major Depressive Disorder, and Generalized Anxiety Disorder within six months of evaluation.\n* Inability to provide informed consent",true,"ALL","18 Years","79 Years",{"count":22,"type":23},210,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study is being done to answer the question: Do people with Parkinson's benefit from a new stepping therapy, and how do people with Parkinson's best learn new steps and rhythms set to music? Researchers will also compare individuals with Parkinson's Disease with people with Mild Cognitive Impairment, and with people with neither of these conditions.\n\nThe purpose of this study is to identify principles of human-music interactions to establish underlying guiding theories for application to music-based rehabilitation for older populations with neurodegenerative disease, leading to more refined and targeted music-based rhythmic movement therapies.",[29,30,31],"Parkinson's Disease (PD)","Alzheimer's Disease (AD) and Related Disorders","Older Adults (60 - 85 Years Old)",[33,34,35,36,37,38,39,40,41],"Dance","Music","Therapy","Rehabilitation","Neurodegenerative","Parkinson's","Alzheimer's","Motor learning","Motor control","RECRUITING","2026-07-07",{"date":45,"type":46},"2026-07-13","ACTUAL",{"date":48,"type":46},"2022-03-25",{"date":50,"type":23},"2028-12",{"name":52,"class":53},"Emory University","OTHER",1,{"id":56,"slug":4,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":18,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":24,"phases":65,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100642015","NCT07647614","A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease","A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets in Combination With Standard of Care for Treating Subjects With Parkinson's Disease","Inclusion Criteria:\n\nA subject is eligible for the study if all of the following apply:\n\n1. With either gender aged ≥ 40 to ≤ 75 years old at Visit 1 (Screening Visit)\n2. Has been diagnosed with idiopathic Parkinson's disease (defined by the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's disease) for ≥ 2 years prior to or at Visit 2 (Day 1)\n3. Has a modified Hoehn and Yahr stage of 2 to 3 while assessed in the medication-off state at Visit 1 (Screening Visit)\n4. With MDS-UPDRS Part III (motor examination) score of 15 to 60 while assessed in the medication-off state at Visit 1 (Screening Visit)\n5. Without motor complications, which is defined as a score of 2 or less on the MDS-UPDRS Part IV score at Visit 1 (Screening Visit)\n6. Has received a stable standard-of-care regimen, as determined by the investigator, during the 12 weeks prior to Visit 2 (Day 1) and is currently on the following antiparkinsonian medications with an average levodopa equivalent daily dose (LEDD) of ≥ 300 mg during the same period, including:\n\n   * Levodopa\n   * Catechol-O-methyl transferase (COMT) inhibitors\n   * Monoamine Oxidase-B (MAO-B) inhibitors\n   * Ergot-derived dopamine receptor agonists\n   * Non ergot-derived dopamine receptor agonists\n   * Others with established levodopa-conversion factors\n7. Has adequate indices as follows at Visit 1 (Screening Visit):\n\n   * Hematology: white blood cells (WBC) should be ≥ 3,000 cells\u002FμL, platelet count should be ≥ 80,000 per μL of blood\n   * Coagulation: prothrombin time, international normalized ratio (INR), and activated partial thromboplastin time (APTT), all of which should be ≤ 1.5 times the upper limit of the normal range (ULN)\n   * Liver function: serum total bilirubin should be ≤ 1.5 times ULN, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) should be ≤ 3 times ULN\n   * Renal function: an estimated glomerular filtration rate (eGFR) should be ≥ 60 mL\u002Fmin\u002F1.73m2, calculated by the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation\n8. Is willing and able to comply with all required study visits and follow-ups required by this protocol\n9. Understands the study procedures and provided written informed consent (including through use of a legally authorized representative, if necessary)\n10. Is able to complete all subject-reported outcome measures\n\nExclusion Criteria:\n\nAny subject meeting any of the exclusion criteria will be excluded from study participation:\n\n1. Has been diagnosed with atypical Parkinson's disease or secondary parkinsonism\n2. Has any of the following neurosurgical intervention for Parkinson's disease within 2 years prior to or at Visit 2 (Day 1):\n\n   * Deep brain stimulation\n   * Pallidotomy\n   * Thalamotomy\n   * Other procedures that may affect motor function\n3. With Mini-Mental State Examination (MMSE) score of \\\u003C 24 at Visit 1 (Screening Visit)\n4. With a lifetime history of significant psychiatric disorder (e.g., alcohol use disorder, drug abuse, or suicide attempt), which in the investigator's opinion, may interfere with study participation\n5. With history of malignancy or current malignancy within 2 years prior to or at Visit 2 (Day 1)\n6. With ongoing or a documented history of within 2 years prior to or at Visit 2 (Day 1) of acute diseases or severe medical conditions, including:\n\n   * Cardiovascular (myocardial infarction, congestive heart failure, New York Heart Association Grade III or IV)\n   * Pulmonary (severe chronic obstructive pulmonary disease, pulmonary hypertension, or other clinically significant respiratory conditions)\n   * Current severe infections, medical history, physical examination findings, or laboratory examination abnormality that in the investigators' opinion are not in stable condition and participating in the study could interfere with the results of the trial or adversely affect the safety of the subject\n7. Administered dopamine-blocking agents within 12 weeks prior to or at Visit 2 (Day 1), including:\n\n   * Typical antipsychotics (e.g., Haloperidol, Chlorpromazine)\n   * Atypical antipsychotics (e.g., Risperidone, Quetiapine or Clozapine)\n8. With clinically significant gastrointestinal disorders that may affect oral drug absorption or tolerability (e.g., inflammatory bowel disease within 12 weeks prior to or at Visit 2 (Day 1) or relevant gastrointestinal surgery recorded on a lifetime basis)\n9. With a history of gout or urolithiasis, or treatment with medications for gout or urolithiasis, within 2 years prior to or at Visit 2 (Day 1)\n10. With known hypersensitivity to any component of the investigational product\n11. Has participated in another clinical trial involving an investigational product, medical device, or surgical procedure within 4 weeks prior to Visit 1 (Screening Visit)\n\n    \\* Note: Subjects enrolled in non-interventional clinical trials will be eligible.\n12. Female subject with childbearing potential who is lactating or has positive serum or urine pregnancy test at Visit 2 (Day 1)\n\n    \\* Note: Female subjects with any of following conditions are considered not with childbearing potential\n    * With menopause ≥ 1 year\n    * Prior surgical procedures resulting in infertility\n    * Documented follicle-stimulating hormone or luteinizing hormone levels consistent with postmenopausal status\n13. Female subjects with childbearing potential or male subjects with partners of childbearing potential who refuse to use highly effective contraceptives from signing informed consent until the end of study (EOS) or early termination (ET) visit\n\n    \\* Note: At least two forms of birth control must be adopted and one of which must be a barrier method. Acceptable forms include:\n    * Established use of oral, injected or implanted hormonal methods of contraception\n    * Placement of an intrauterine device (IUD) or intrauterine system (IUS)\n    * Barrier methods of contraception: condom, or occlusive cap (diaphragm or cervical\u002Fvault caps)\n14. Is an employee of the investigator's site, the sponsor, or its delegate (e.g., contract research organization) who is directly involved in the conduct of the study","40 Years","75 Years",{"count":64,"type":23},105,[66],"PHASE2","The goal of this clinical trial is to learn if this study drug, ENERGI-F705 Tablets, is safe and works to treat participants who have Parkinson's disease and are currently on standard-of-care antiparkinsonian medications. The main question it aims to answer is:\n\nDoes ENERGI-F705 Tablets work to treat Parkinson's disease when used with standard-of-care treatment?\n\nInvestigators will compare the three treatment groups, high-dose ENERGI-F705 Tablets (120 milligrams twice daily), low-dose ENERGI-F705 Tablets (60 milligrams twice daily), and placebo tablets (a look-alike substance that contains no drug), to see if ENERGI-F705 Tablets work to treat Parkinson's disease.\n\nParticipants will:\n\n* Take the study drugs twice a day for 72 weeks in the treatment group\n* Take routine use of standard-of-care antiparkinsonian medications throughout the study\n* Visit the outpatient department at scheduled visits, ranging from Day 1 to approximately every 1 to 4 weeks thereafter, for checkups and tests",[29],[70,71,72,73,74],"Phase II","Randomized","Double blind","ENERGI","Parkinson' disease","NOT_YET_RECRUITING","2026-06-30",{"date":78,"type":46},"2026-07-02",{"date":80,"type":23},"2026-12-01",{"date":82,"type":23},"2030-01-01",{"name":84,"class":85},"Energenesis Biomedical Co., Ltd.","INDUSTRY",2,{"id":88,"slug":4,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":17,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":24,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":86},"100637666","NCT07604116","A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA","A Non-Randomized, Open-Label Phase I Study to Evaluate the Safety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With Multiple System Atrophy, and Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Sign the informed consent form approved by IEC.\n* Male or female participants aged ≥40 years old.\n* Adequate organ functions.\n* Proper contraception methods.\n* Willingness to follow the study procedures.\n* Additional inclusion criteria for healthy volunteers: Good health status; no history of motor disorders or cognitive disorders.\n* Additional inclusion criteria for MSA: Diagnosed with clinically established or clinically probable MSA according to the MDS MSA criteria (2022). If previously treated, the treatment regimen for MSA must have been stable for at least 4 weeks with no planned adjustments in the near term.\n* Additional inclusion criteria for PD: Diagnosed with clinically established or clinically probable PD according to the MDS PD criteria (2015). If previously treated, the treatment regimen for PD must have been stable for at least 4 weeks with no planned adjustments in the near term.\n\nExclusion Criteria:\n\n* Being pregnant or lactating.\n* History of other severe neurological disorders.\n* History of serious or uncontrolled medical condition.\n* Active HBV\u002FHCV\u002FHIV infection, etc.\n* History of abuse of drugs or alcohol within 1 year.\n* Allergy to the study drug.\n* Intolerance to PET\u002FCT or MRI (e.g. claustrophobia).\n* Any interventional clinical studies within 30 days.\n* Radiation exposure dose exceeding 50 mSv\u002Fyear.\n* Prior therapy targeting α-Syn.\n* Other ineligible conditions for this study.",{"count":94,"type":23},30,[96],"PHASE1","The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.",[99,29],"Multiple System Atrophy (MSA)","2026-06-29",{"date":76,"type":46},{"date":103,"type":46},"2026-06-15",{"date":105,"type":23},"2027-02",{"name":107,"class":85},"Synusight Biotech (Shanghai) Co., Ltd.",{"id":109,"slug":4,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":18,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":24,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100645363","NCT07681219","LRRK2 Parkinson's Disease Fingerprint","LRRK2 Associated Parkinson's Disease: Definition of a Clinical, Molecular and Neurophysiological Fingerprint","NEU-PD","Inclusion Criteria:\n\n* age 30-80 years,\n* clinically established diagnosis of PD according to the Movement Disorders Society (MDS) diagnostic criteria,\n* Hoehn \\& Yahr (H\\&Y) stage between 1 and 3,\n* 10 patients with a LRRK2 associated parkinsonism and 10 with sporadic PD tested with a NGS panel and MLPA for PD associated genes,\n* ability to provide informed consent.\n\nExclusion Criteria:\n\n* Active or history of other neurological disorders,\n* active infectious disease or history within the previous 4 weeks,\n* continuative therapy (at least 1 week) with NSAIDs or steroids within the previous 12 weeks,\n* active malignancy, autoinflammatory or autoimmune diseases or history within the previous 3 years;\n* alcohol or drug abuse or dependence\n* any contraindication to the execution of the MRI (including claustrophobia).","30 Years","80 Years",{"count":118,"type":23},20,[26],"The goal of this interventional monocentric study is to identify molecular and clinical markers of LRRK2-related Parkinson's disease through blood markers analysis and deep clinical phenotyping. Patients who meet the inclusion criteria, after signing the informed consent form will be clinically evaluated by a neurologist expert in movement disorders. Eventually, patients will undergo a blood sample collection, a brain MRI, and a high density EEG. All data will be collected using an ad hoc electronic Case Report Form (CRF) developed for the study",[122,123],"Parkinsons Disease (PD)","LRRK2","2026-06-26",{"date":78,"type":46},{"date":127,"type":23},"2026-09-01",{"date":129,"type":23},"2029-09-01",{"name":131,"class":53},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":133,"slug":4,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":18,"minAge":61,"maxAge":116,"enrollmentInfo":138,"targetDuration":4,"studyType":24,"phases":140,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":54},"100639756","NCT07610369","The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","PSI-PD","Inclusion Criteria:\n\n* Able to understand and provide informed consent\n* Comfortable speaking and writing in English\n* Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an \"on\" phase (time when medication\u002FDBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)\n* Have no changes in medication or major surgical procedures anticipated for treatment duration\n* Have a score \\>\u002F=20 on the Beck Depression Inventory-2 (BDI-2), consistent with moderate or greater depressive symptom severity, at Baseline.\n* For people who can become pregnant: agree to use highly effective contraception from entry into the trial through Day B30 assessments (4 weeks after the second psilocybin administration session) and agree to not breastfeed. Acceptable methods of contraception are: An intrauterine device (IUD), hormone-based contraceptives (birth control pills) , condoms (internal or external) must be used with another method (other than spermicide), and complete abstinence from sexual activity that could result in pregnancy.\n* Agree that for one week preceding each psilocybin session, they will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement except when approved by the research team. Exceptions will be evaluated by the research team and assessed for safety. Agree to abstain from all tobacco and nicotine use for the duration of the study.\n* Agree to consume approximately the same amount of caffeine-containing beverages that they usually consume before arriving at the research unit on the mornings of psilocybin administration sessions.\n* Agree to avoid sedative-hypnotic medications (e.g., benzodiazepines, zolpidem, zopiclone, zaleplon) taken on an as-needed basis for a minimum of 5 half-lives prior to each psilocybin administration session and for 24 hours after each psilocybin administration session.\n* Agree to avoid opioid medications taken on an as-needed basis for a minimum of 5 half-lives prior to each psilocybin administration session and for 24 hours after each psilocybin administration session.\n* Agree not to use products or substances containing Δ9-tetrahydrocannabinol (THC) and\u002For cannabidiol for at least 7 days prior to each psilocybin administration session and for 24 hours after each psilocybin administration session.\n* Agree to not use non-prescribed narcotics (eg. heroine, fentanyl), depressants (eg. Barbiturates, benzodiazepines) and\u002For inhalants for the duration of participation in the trial.\n* Agree not to consume alcoholic beverages for at least 24 hours prior to and 24 hours following each psilocybin administration session.\n* Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating care and is available for consultation with the study medical monitor.\n\nExclusion Criteria:\n\n* Any indication of forms of parkinsonism other than idiopathic Parkinson's disease.\n* Cognitive impairment, defined as a Montreal Cognitive Assessment (MoCA) score \\\u003C24.\n* Symptomatic orthostatic hypotension.\n* Currently receiving electroconvulsive therapy (ECT) or treatment via transcranial magnetic stimulation (TMS). Previous treatment with ECT and\u002For TMS is permitted; last treatment must be at least 30 days prior to entry into this trial.\n* Treatment in a clinical trial within 30 days of entry into this trial or treatment with another investigational drug or other intervention within 30 days or 5 half-lives, whichever is longer, prior to entry into this trial.\n* Pregnancy as indicated by a positive urine pregnancy test during screening, lactation, or the intention of becoming pregnant within 3 months of entry into this trial.\n* Current severity of psychiatric symptoms warranting immediate treatment as determined by the study medical staff (e.g. due to inability to provide for basic needs\u002Fsafety). The study medical staff will assess these individuals, determine the appropriate level of care, and coordinate with the individual's primary providers to ensure close follow-up.\n* High risk of self-harm\u002Fsuicide, as determined by the Columbia-Suicide Severity Rating Scale (C-SSRS) risk screen, specifically: participant answers \"yes\" to item 4 or 5 suggesting intent to act on suicidal thoughts OR participant has made a serious suicide attempt within the 12 months prior to entry into this trial.\n* History of meeting DSM-5 criteria for a schizophrenia spectrum disorder, other psychotic disorder, or a mood disorder with psychotic features.\n* History of delusional symptoms or any other psychotic symptoms accompanied by a loss of insight. Exceptions may be made at the investigators' discretion in cases of a history of psychotic symptoms that were attributable to substance or medication use.\n* Current delusional symptoms or any other psychotic symptoms accompanied by a loss of insight.\n* History of a schizophrenia spectrum disorder in a first-degree relative.\n* History of bipolar disorder 1 in a first-degree relative, in whom illness onset was prior to age 40.\n* Current or history of meeting DSM-5 criteria for a bipolar disorder.\n* Current or history within the last 2 years of meeting DSM-5 criteria for a moderate or severe alcohol or drug use disorder, excluding caffeine.\n* Currently meeting DSM-5 criteria for another psychiatric condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin treatment procedures as determined by the investigators.\n* History of meeting DSM-5 criteria for Hallucinogen Persisting Perception Disorder (HPPD).\n* History of using any psychedelic substances including psilocybin, lysergic acid diethylamide (LSD), mescaline (and natural products containing mescaline including peyote and San Pedro cactus), N,N-Dimethyltryptamine (DMT), natural products containing DMT including ayahuasca and 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), ibogaine, 2C compounds, 3,4-methylenedioxy-methamphetamine (MDMA), or methylone during the past 6 months at dosages and\u002For frequencies determined clinically significant by the investigators.\n* Cancer with known central nervous system (CNS) involvement, CNS infection, or other major CNS disease aside from PD.\n* Epilepsy or other seizure disorder in adulthood.\n* Supplemental oxygen requirement.\n* Allergy or intolerance to any of the materials contained in the drug products.\n* Renal insufficiency defined as creatinine clearance \\\u003C 40 ml\u002Fmin using Cockraft and Gault equation\n* Insufficiently managed endocrine conditions, including diabetes mellitus and clinically significant thyroid dysfunction.\n* Cardiovascular conditions, including:\n\n  * Elevated blood pressure defined as systolic blood pressure (SBP) \\>150 or diastolic blood pressure (DBP) \\>95 taken during Enrollment\n  * Tachycardia defined as heart rate (HR) \\>90 beats per minute taken during Enrollment\n  * Bradycardia defined as HR \\\u003C50 bpm taken during Enrollment\n  * Angina\n  * History of stroke within the past year\n  * Clinically significant ECG abnormality as determined by the investigators, including but not limited to QTc \\> 450\n* Hepatic dysfunction as indicated by any of the following laboratory values:\n\n  * AST \\> 3 x upper limit of normal\n  * ALT \\> 3 x upper limit of normal\n  * Total bilirubin \\> 3.0 mg\u002Fdl\n* Use of any of the following concomitant medications AND inability\u002Funwillingness to discontinue for at least 5 times the elimination half-life of the agent (specific exceptions are noted) prior to psilocybin administration, including:\n\n  * Agents that may be associated with serotonin syndrome:\n\n    * MAO inhibitors (participants must have discontinued 2 weeks prior to baseline)\n    * St. John's Wort\n    * S-adenosyl-methionine (SAM-e)\n    * 5-Hydroxytryptophan (5-HTP)\n    * Dextromethorphan\n    * Opioids (e.g., codeine, fentanyl, hydrocodone, meperidine, tramadol)\n    * Lithium\n    * Linezolid\n    * Buspirone\n  * Agents that may interact with psilocybin metabolism\u002Feffects:\n\n    * Serotonin antagonists (e.g., cyclobenzaprine, ondansetron)\n    * Antipsychotics\n    * Other dopamine antagonists (e.g., metoclopramide, promethazine, prochlorperazine)\n    * Nicotine\n    * Modulators of uridine diphosphate (UDP) or glucuronosyltransferase (UGT) (e.g. valproate, diclofenac, mefenamic acid, verapamil, ketoconazole, itraconazole, probenecid, phenobarbital, protease inhibitors)\n    * L-methyl folate (\\>\u002F= 7.5mg\u002Fday)\n    * Efavirenz\n  * Agents that may increase the risk of psychotic symptoms:\n\n    * Stimulants (e.g. modafinil, methylphenidate, atomoxetine, methamphetamine, cocaine, amphetamine derivatives)\n    * Anticholinergics (e.g. benztropine, trihexyphenidyl, scopolamine, hyoscyamine)\n    * Systemic steroids\n  * Tricyclic antidepressants\n* Other medical condition or diagnosis, concomitant medication(s), physical exam finding, laboratory abnormality or health risk identified that precludes participation in study procedures due to safety or feasibility concerns at the discretion of the investigators.",{"count":139,"type":23},40,[66],"The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.",[143,29],"Depression",[145,143,146,147,148],"Parkinson's Diesease","Psilocybin","Psilocybin therapy","Movement disorder","2026-06-24",{"date":100,"type":46},{"date":152,"type":23},"2026-06",{"date":154,"type":23},"2030-06",{"name":156,"class":53},"Yale University",{"id":158,"slug":4,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":116,"enrollmentInfo":163,"targetDuration":4,"studyType":24,"phases":165,"briefSummary":167,"conditions":168,"keywords":171,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":86},"100619717","NCT07348250","Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease","An Open-label Study to Evaluate Brain α-Synuclein Deposition Using Positron Emission Tomography (PET) and [18F]MK-0947 in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Signed informed consent prior to any study procedures\n* Women of childbearing potential: abstinent or use 2 contraception methods (one barrier) during study and 90 days post last injection\n* Men: use 2 contraception methods and refrain from sperm donation during study and 90 days post last injection\n* PD \\& HE participants: Age 40-80 years; HP participants: Age 18-50 years\n* Adequate circulation and normal clotting for arterial cannulation (if applicable)\n* HE participants: no neurological disorder, no first-degree relative with idiopathic PD\n* HP participants: healthy with no clinically relevant findings\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent\n* Clinically significant hepatic, renal, cardiovascular, pulmonary, or systemic illness\n* Pregnant or breastfeeding\n* Contraindication to PET or MRI procedures (e.g., implants, claustrophobia)\n* History of severe allergic reactions to PET tracers or related compounds\n* Current or prior participation in investigational drug study within 30 days\n* Any condition that may interfere with study conduct or participant safety",{"count":164,"type":23},22,[166],"EARLY_PHASE1","This clinical study is being conducted to learn more about a new imaging drug called \\[18F\\]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD). PD is a condition that affects movement, balance, and thinking. The drug works with a type of scan called PET (Positron Emission Tomography) to show areas of the brain where a protein called α-synuclein builds up. This buildup is linked to PD and other brain disorders.\n\nThe main goal of this study is to find out if \\[18F\\]MK-0947 is safe for people and if it works well to show α-synuclein in the brain. The study will also look at how the drug moves through the body and how much radiation it gives off. Researchers hope this information will help develop better tools for diagnosing PD and tracking how it changes over time.\n\nWho can join? Adults who have PD or who are healthy may be able to take part. Participants will have screening tests to make sure they qualify.\n\nWhat does participation involve? People in the study will have PET scans, blood tests, and other safety checks. Some participants will also have an MRI scan. The study is divided into two parts: Part 1 looks at how the drug works in the brain of PD patients and healthy elderly participants, and Part 2 measures radiation levels in healthy participants.\n\nWhy is this important? There is currently no cure for PD, and better imaging tools could help researchers develop new treatments. By joining this study, participants will help advance research that may improve care for people with PD and similar conditions in the future.",[29,169,170],"Parkinson's Disease","Parkinson's Disease (Disorder)",[172,173,174,175],"alpha-synuclein","α-synuclein","Neurodegeneration","MK-0947",{"date":124,"type":46},{"date":178,"type":46},"2025-12-08",{"date":180,"type":23},"2026-12",{"name":182,"class":53},"Invicro",{"id":184,"slug":4,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":24,"phases":190,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":4},"100641196","NCT07641556","The Effects of Tele-Rehabilitation-Based Dual-Task Upper Extremity Training in Patients With Parkinson's Disease","Investigating the Effects of Tele-Rehabilitation-Based Dual-Task Upper Extremity Training in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Having been diagnosed with Parkinson's disease by a neurologist according to the UK Brain Bank criteria\n* Being in stage 3 or higher according to the Hoehn-Yahr Scale\n* Having a caregiver capable of providing the necessary assistance during tele-rehabilitation sessions and using the required equipment and programs.\n* Having the device and software to conduct remote video calls for tele-rehabilitation\n\nExclusion Criteria:\n\n* Presence of a neurological disease other than Parkinson's disease\n* Cognitive impairment (Standardized Mini Mental Test score less than 24)\n* Having undergone deep brain stimulation surgery\n* Having a visual, auditory, or perceptual problem\n* Having any orthopedic, rheumatological, or other condition that may affect hand functions",{"count":139,"type":23},[26],"The aim of this study is to compare the effects of tele-rehabilitation-based synchronous and asynchronous dual-task upper extremity training with clinical based dual-task upper extremity training and conventional single-task upper extremity training in patients with Parkinson's disease. The main questions it aims to answer are:\n\n* Whether there are differences in motor symptoms, hand dexterity, upper extremity functions, grip strength, executive functions, daily living activities, and treatment satisfaction between tele-rehabilitation-based synchronous and asynchronous dual-task upper extremity training, clinical-based dual-task upper extremity training, and conventional single-task upper extremity training in patients with Parkinson's disease.\n* Whether there is a difference in telemedicine satisfaction between tele-rehabilitation-based synchronous and asynchronous dual-task upper extremity training in patients with Parkinson's disease.\n\nResearchers will compare conventional single-task upper extremity training, clinical-based dual-task upper extremity training, tele-rehabilitation-based synchronous upper extremity training and tele-rehabilitation-based asynchronous upper extremity training.\n\nParticipants will:\n\n* Receive upper extremity exercise training at the study clinic or home, twice a week for approximately 60 minutes each time, for 6 weeks.\n* Participate in assessments at the study clinic before and after exercise training.",[29],[169,194,195,196],"Dual Task Training","Upper Extremity","Tele-Rehabilitation","2026-06-16",{"date":199,"type":46},"2026-06-18",{"date":201,"type":23},"2026-07-01",{"date":203,"type":23},"2026-09-15",{"name":205,"class":53},"Saglik Bilimleri Universitesi",{"id":207,"slug":4,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":24,"phases":214,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":222,"leadSponsor":223,"locationsCount":54},"100641386","NCT07641569","Comparison of Two Different Dual-Task Training Methods in Patients With Parkinson's Disease","Comparison of Motor-Motor and Cognitive-Motor Dual-Task Training in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Having been diagnosed with Parkinson's disease by a neurologist according to the UK Brain Bank criteria.\n* Being in stages 1-3 according to the Hoehn-Yahr Scale.\n\nExclusion Criteria:\n\n* Presence of a neurological disease other than Parkinson's disease\n* Cognitive impairment (Standardized Mini Mental Test score less than 24)\n* Having undergone deep brain stimulation surgery\n* Having a visual, auditory, or perceptual problem\n* Having any orthopedic, rheumatological, or other condition that may affect walking and balance.",{"count":213,"type":23},39,[26],"The aim of this study is to compare the effectiveness of motor-motor dual-task training and cognitive-motor dual-task training in patients with Parkinson's disease.The main questions it aims to answer are:\n\n\\- Whether there is a difference between motor-motor dual-task training and cognitive-motor dual-task training in patients with Parkinson's disease in terms of their effects on motor symptoms, balance, gait, functional mobility, activities of daily living, dual-task activities, cognitive functions, and balance confidence.\n\nResearchers will compare single-task training, motor-motor dual task training and cogvitive-motor dual task training.\n\nParticipants will:\n\n* Receive exercise training at the study clinic twice a week for approximately 45 minutes each time, for 6 weeks.\n* Participate in assessments at the study clinic before and after exercise training.",[29],[169,194,218,219],"Motor-Motor","Cognitive-Motor",{"date":199,"type":46},{"date":103,"type":46},{"date":203,"type":23},{"name":205,"class":53},{"id":225,"slug":4,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":24,"phases":233,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":54},"100609382","NCT07213856","Nutritional Intervention for Constipation Symptoms in Patients With Parkinson's Disease","Nutritional Intervention for Constipation Symptoms in Patients With Parkinson's Disease: A Randomized Clinical Trial","NUTRI-GUT-PD","Inclusion Criteria:\n\n* Adults with a previous diagnosis of Parkinson's disease\n* On a stable dose of levodopa for at least 3 months\n* Diagnosis of Functional Constipation by the Rome IV protocol\n\nExclusion Criteria:\n\n* Diagnosis of atypical or secondary parkinsonism\n* Hoehn and Yahr stage greater than 2\n* Presence of severe neurological or psychiatric disorders that impair the ability to participate in study procedures\n* Previous diagnosis of dementia\n* Presence of comorbidities such as active cancer, chronic obstructive pulmonary disease (COPD), heart failure, and\u002For chronic kidney disease\n* History of gastrointestinal cancers, inflammatory bowel diseases, or surgeries involving the gastrointestinal tract\n* Constipation secondary to clinical conditions such as hypothyroidism or diabetes mellitus\n* Use of opioids\n* Use of probiotics or antibiotics in the past 8 weeks\n* Continuous use of laxatives in the past 8 weeks\n* Presence of severe dysphagia according to the Functional Oral Intake Scale (FOIS)\n* Individuals receiving enteral or parenteral nutrition\n* Individuals under nutritional follow-up in the past 3 months",{"count":232,"type":23},54,[26],"The goal of this clinical trial is to evaluate whether a dietitian-guided nutritional intervention can improve constipation symptoms in people with Parkinson's disease (PD). The main questions it aims to answer are:\n\n* Can a dietitian-guided nutritional intervention increase the number of weekly bowel movements in individuals with PD and functional constipation?\n* Can this intervention positively influence gut microbiota composition, dietary intake, and nutritional status?\n\nResearchers will compare the intervention group to a control group that will receive general dietary guidance only after the study period, to see if the intervention leads to improvements in bowel function and related health outcomes.\n\nParticipants will:\n\n* Follow a diet plan developed by a dietitian, based on dietary reference intakes and tailored to the needs of individuals with PD and constipation\n* Participate in follow-up sessions with the dietitian for 3 months\n* Complete assessments at baseline, midpoint, and end of the intervention to evaluate bowel function, constipation symptoms, gut microbiota, nutritional status, and diet quality",[122,236],"Constipation - Functional",[238,239,240,241,242,243,244,245,246],"Microbiota","Diet","Diet, Protein-Restricted","Diet Therapy","Diet, Healthy","Nutrition Therapy","Constipation","Non-Motor Symptoms","Nutritionists",{"date":197,"type":46},{"date":249,"type":46},"2026-04-02",{"date":251,"type":23},"2029-08",{"name":253,"class":53},"Hospital de Clinicas de Porto Alegre",{"id":255,"slug":4,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":18,"minAge":61,"maxAge":116,"enrollmentInfo":259,"targetDuration":4,"studyType":24,"phases":260,"briefSummary":261,"conditions":262,"keywords":263,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":269,"leadSponsor":271,"locationsCount":54},"100641070","NCT07656129","Immediate Effects of External Trigeminal Nerve Stimulation on Motor Dysfunction in Parkinson's Disease","Inclusion Criteria:\n\n1. Patients with idiopathic Parkinson's disease diagnosed by two neurologists, according to the Chinese diagnostic criteria for Parkinson's disease formulated in 2020 by the Chinese Parkinson's Disease and Movement Disorders Society based on the MDS Clinical Diagnostic Criteria for Parkinson's disease.\n2. Hoehn and Yahr stage 1-5 in the medication ON state.\n3. Mini-Mental State Examination (MMSE) score \\>24.\n4. Stable antiparkinsonian medication for at least 1 month before the trial.\n5. No history of orthopedic or musculoskeletal disorders, and no other conditions that may affect balance or gait, such as ophthalmologic disorders.\n6. No history of epilepsy, intracranial tumors, or other neurological disorders; no severe psychiatric disorders, such as schizophrenia; and no long-term use of antipsychotic medications.\n7. Age between 40 and 80 years.\n8. Ability to cooperate with all assessments and eTNS treatment, and provision of written informed consent.\n\nExclusion Criteria:\n\n1. Secondary parkinsonism or atypical parkinsonian syndromes.\n2. Current use of anticholinergic medications.\n3. Contraindications to non-invasive electrical neuromodulation.\n4. Previous eTNS treatment within the past 6 months.\n5. Severe neurological, renal, cardiovascular, hepatic, or other major systemic diseases.\n6. Inability to complete clinical assessments or refusal to provide written informed consent.",{"count":94,"type":23},[26],"Parkinson's disease (PD), the most common movement disorder, is characterized by motor symptoms including tremor, rigidity, bradykinesia, and postural instability. These symptoms substantially impair quality of life and increase the risk of falls, disability, and accidental injury, representing a major therapeutic challenge.\n\nExternal trigeminal nerve stimulation (eTNS), a non-invasive neuromodulation technique, has shown promising potential in PD and other movement disorders. A clinical study published in 2017 suggested that trigeminal nerve stimulation may contribute to the alleviation of motor symptoms in patients with PD. In 2023, the U.S. Food and Drug Administration cleared the Portable Neuromodulation Stimulator (PoNS) as an adjunctive treatment for gait impairment caused by multiple sclerosis; the lingual nerve is a branch of the mandibular division of the trigeminal nerve. In the same year, experimental evidence showed that trigeminal nerve stimulation could activate intracranial dopaminergic neurons and modulate dopamine release in mice. These findings suggest substantial potential for eTNS in modulating motor dysfunction in PD, although high-level clinical evidence remains lacking.\n\nThis randomized, within-subject study will evaluate the immediate effects of eTNS at different stimulation frequencies on motor dysfunction in patients with PD. Gait parameters will be quantitatively assessed using the IDEEA gait system, together with the MDS-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS Part III), Tinetti Gait Scale, and Hoehn and Yahr Scale.\n\nThis within-subject study comprises three 20-min stimulation conditions: 120-Hz eTNS, 40-Hz eTNS, and sham stimulation. Each patient with Parkinson's disease will complete all conditions in a single session in randomized order. Instrumented gait analysis, together with motor and gait rating scales, will be used to quantify immediate post-stimulation changes in gait and motor function relative to baseline.",[29],[264,169,265],"external Trigeminal Nerve Stimulation","Motor dysfunction","2026-06-14",{"date":199,"type":46},{"date":103,"type":23},{"date":270,"type":23},"2026-07-15",{"name":272,"class":53},"Zhengli Di",{"id":274,"slug":4,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":18,"minAge":61,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":24,"phases":282,"briefSummary":284,"conditions":285,"keywords":287,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":301},"100614837","NCT07284784","A Study of Buntanetap in Participants With PD","An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Parkinson's Disease","Inclusion Criteria:\n\n1. Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and\n\n   a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE \\\u003C21 at screening.\n\n   b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.\n\n   i. Female or male adults aged 40 to 85 years. ii. H\\&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.\n2. Have a support person who will accompany the participant on study visits at designated times.\n3. Female participants of childbearing potential\\* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:\n\n   1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,\n   2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,\n   3. Intrauterine device (IUD),\n   4. Intrauterine hormone-releasing system (IUS),\n   5. Bilateral tubal occlusion,\n   6. Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),\n   7. Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).\n\n      * Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.\n\n   Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54\n4. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:\n\n   1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,\n   2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,\n   3. IUD,\n   4. IUS,\n   5. Bilateral tubal occlusion.\n5. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.\n6. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.\n\n   1. Standard of care anti-parkinsonian medication,\n   2. Cholinesterase inhibitors and\u002For memantine medication,\n   3. Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,\n   4. Mood-stabilizing psychotropic agents including, but not limited to, lithium,\n7. Adequate visual and hearing ability (physical ability to perform all the study assessments).\n8. Good general health with no disease expected to interfere with the study.\n\nExclusion Criteria:\n\n1. Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion\u002Fexclusion criteria).\n2. A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.\n3. A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.\n4. A history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.\n5. Bradycardia (\\\u003C50 bpm) or tachycardia (\\>100 bpm) on the ECG at screening and deemed medically significant by the PI.\n\n   Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54\n6. Uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.\n7. Clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] \\\u003C50 mL\u002Fmin\u002FBSA \\[body surface area\\]) or hepatic impairment (Alkaline phosphatase \\[ALP\\] \\> 2.0X the upper limit of normal \\[ULN\\] and\u002For total bilirubin \\> 2.0X ULN).\n8. Any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase \\[AST\\] or alanine aminotransferase \\[ALT\\]) greater than twice ULN will be excluded.\n9. Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.\n10. Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).\n11. Alcohol \u002F Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.\n12. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.\n13. A learning disability or developmental delay.\n14. Participants whom the site PI deems to be otherwise ineligible.\n15. A known allergy to the investigational drug or any of its components.\n\n    Inactive ingredients of the investigational medicinal product:\n    * Silicified microcrystalline cellulose\n    * Dibasic calcium phosphate dihydrate\n    * Mannitol\n    * Stearic acid\n    * Hypromellose (capsule shells structure)\n    * Titanium dioxide (opacifier of the capsule shells)\n16. Is currently pregnant, breast-feeding, and\u002For lactating.\n17. Uncontrolled hypertension (systolic \\>160mmHg and\u002For diastolic \\>95mmHg) or hypotension (systolic \\\u003C90mmHg and\u002For diastolic \\\u003C60 mmHg) and deemed medically significant by the PI.","85 Years",{"count":281,"type":23},500,[66,283],"PHASE3","This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.",[29,286],"Deep Brain Stimulation",[169,288,286,289,290,291,292],"PD","DBS","buntanetap","Open-Label","posiphen","2026-06-11",{"date":103,"type":46},{"date":296,"type":46},"2026-01-09",{"date":298,"type":23},"2029-11",{"name":300,"class":85},"Annovis Bio Inc.",27,{"id":303,"slug":4,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":18,"minAge":309,"maxAge":62,"enrollmentInfo":310,"targetDuration":4,"studyType":24,"phases":312,"briefSummary":313,"conditions":314,"keywords":315,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":139},"100588678","NCT06944522","A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease","exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinson's Disease","exPDite-2","Inclusion Criteria:\n\n* Diagnosis of clinically established PD as defined by the International Parkinson and Movement Disorders Society\n* Individual of any sex ≥45 to ≤75 years of age at informed consent\n* Robust and clear response to DA therapy as defined by MDS-UPDRS Part III\n* ≥4 and \\\u003C12 years from time of PD diagnosis at informed consent\n* Must demonstrate responsiveness to levodopa therapy\n* Receiving medical therapy for the treatment of PD symptoms\n* ≥2.5 hours of daily OFF-time\n* Vaccinated per current national guidelines or local practice for patients with altered immunocompetence\n\nExclusion Criteria:\n\n* PD presenting with recurrent falls\n* Diagnosis of primary mitochondrial disorder, epilepsy, stroke, multiple sclerosis, or clinical features suggestive of a neurodegenerative disease other than PD, including multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, or Lewy body dementia\n* Any current or relevant previous history of serious, severe, or unstable physical, neurological, or psychiatric illness that may interfere with study participation, participant's safety, or assessment of endpoints per investigator's judgment\n* History of gene therapy or cell therapy\n* Prior treatment with intrajejunal or subcutaneous infusion therapies for PD\n* Prior surgical or radiation therapy to the brain, including deep brain stimulation (DBS) and lesion therapy, or prior history of intradural spinal cord surgery\n* Contraindication to surgery, general anesthesia, cell therapy, immunosuppression, or other required drugs, or anything that prevents use of PET or MRI\n* Any active infection (including but not limited to HIV, HCV, HBV, CMV, syphilis, or tuberculosis) or condition that, in the opinion of the investigator could put the participant at significant risk from immunosuppression or impact the participant's ability to perform study assessments\n* Current or previously active malignant disease within the past 5 years\n* Chronic immunosuppressive therapy\n* Receipt of another investigational therapy within 5 half-lives of the active treatment\n* Pregnancy or breastfeeding","45 Years",{"count":311,"type":23},102,[283],"Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).",[122],[307,316,317,318,319],"Cell Therapy","Cellular Therapy","Dopaminergic Neuronal Cell Therapy","Parkinsons Disease","2026-06-04",{"date":322,"type":46},"2026-06-05",{"date":324,"type":46},"2025-06-17",{"date":326,"type":23},"2032-03",{"name":328,"class":85},"BlueRock Therapeutics",{"id":330,"slug":4,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":24,"phases":336,"briefSummary":337,"conditions":338,"keywords":339,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":54},"100628136","NCT07457710","Remote Haptic Rehabilitation for Parkinson's Disease","Enhancing Parkinson's Disease Rehabilitation Through Remote Haptic Guidance: Field Study","Inclusion Criteria:\n\n* Over 18 years old\n* Diagnosed with PD\n\nExclusion Criteria:\n\n* Hoehn and Yahr stage outside 1-3\n* Lives outside the 48 contiguous states in the USA\n* Unable to move hands and head without assistance\n* Unable to remain seated in an upright position for up to an hour",{"count":118,"type":23},[26],"Individuals with Parkinson's Disease (PD) often have motor difficulties that can negatively impact daily activities and their quality of life. Research has shown that to slow the progression of these symptoms, patients should partake in effective physical rehabilitation. However, effective physical rehabilitation has many barriers, including timing, cost, and other personal or system-level challenges. The purpose of this study is to evaluate the haptic remote rehabilitation system for patients with PD using a randomized controlled trial (RCT) in a field environment.",[29],[169,340,341],"Haptic","Remote Rehabilitation","2026-06-03",{"date":322,"type":46},{"date":345,"type":46},"2026-03-25",{"date":347,"type":23},"2027-06-30",{"name":349,"class":53},"Virginia Polytechnic Institute and State University",{"id":351,"slug":4,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":18,"minAge":357,"maxAge":279,"enrollmentInfo":358,"targetDuration":4,"studyType":24,"phases":360,"briefSummary":361,"conditions":362,"keywords":363,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":54},"100638604","NCT07625540","Subthalamic Nucleus-Targeted Transcranial Temporal Interference Stimulation for Motor and Non-Motor Symptoms in Parkinson's Disease","Study on the Efficacy and Safety of Subthalamic Nucleus (STN)-Targeted Transcranial Temporal Interference Stimulation (tTIS) for Motor and Non-Motor Symptoms in Parkinson's Disease (PD): A Randomized, Double-Blind, Controlled Exploratory Trial","STN-tTIS-PD","Inclusion Criteria:\n\n* Aged 50-85 years, male or female.\n* Diagnosed with \"clinically established\" or \"clinically probable\" Parkinson's disease according to the 2015 MDS Clinical Diagnostic Criteria for Parkinson's Disease.\n* Hoehn-Yahr stage ≥ 2, and judged by the investigator to be able to cooperate in completing scale-based assessments and MRI examinations.\n* Stable regimen of anti-Parkinsonian medication for at least 4 weeks before enrollment, and agreement to maintain a stable regimen during the main study phase unless medically necessary to change.\n* Written informed consent signed by the study participant.\n\nExclusion Criteria:\n\n* Non-primary Parkinson's disease or other parkinsonism \u002F atypical parkinsonism.\n* Previous receipt of invasive neuromodulation therapies such as deep brain stimulation (DBS) or other intracranial implantation\u002Fstereotactic brain surgery.\n* Presence of contraindications or high-risk conditions for transcranial electrical stimulation (e.g., incompatible metal implants\u002Fimplantable electrical stimulation devices, etc.), or judged by the investigator as unsuitable to receive transcranial electrical stimulation.\n* Receipt of non-invasive neuromodulation interventions such as transcranial magnetic stimulation or transcranial electrical stimulation within the past six months.\n* Presence of contraindications to MRI or inability to tolerate MRI examination.\n* Significant cognitive impairment or severe psychiatric symptoms that prevent completion of assessments or result in poor compliance.\n* New initiation or dose adjustment of medications or treatments that significantly affect sleep architecture\u002Fconsciousness status within the past 4 weeks.\n* History of epilepsy.\n* Pregnancy or breastfeeding.\n* Any other condition judged by the investigator as unsuitable for participation in the study.","50 Years",{"count":359,"type":23},32,[26],"Transcranial temporal interference stimulation (tTIS) is a non-invasive deep brain stimulation method. This study aims to comprehensively explore the efficacy and safety of bilateral subthalamic nucleus (STN) tTIS on motor and non-motor symptoms in patients with Parkinson's disease (PD).",[29],[364,365,366,367,368],"Parkinson's disease","transcranial Temporal Interference Stimulation","subthalamic nucleus","motor symptoms","non-motor symptoms","2026-06-02",{"date":320,"type":46},{"date":372,"type":46},"2026-05-20",{"date":374,"type":23},"2027-04",{"name":376,"class":53},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":378,"slug":4,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":24,"phases":384,"briefSummary":385,"conditions":386,"keywords":388,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":394,"leadSponsor":396,"locationsCount":54},"100638966","NCT07606547","Biomechanical Effects of EMST® on Swallowing Function in Parkinson's Disease","Biomechanical Effects of Expiratory Muscle Strength Training (EMST®) on Swallowing Function in Parkinson's Disease - a Prospective High-resolution Manometry Study","Inclusion Criteria:\n\n* diagnosis of Parkinson's disease,\n* PD-related dysphagia as objectively diagnosed with FEES\n\nExclusion Criteria:\n\n* severe dementia, not able to give consent\n* dysphagia related to other diagnoses",{"count":94,"type":23},[26],"The aim of this non-randomized intervention study is to investigate the detailed effects of a structured four-week EMST® training program on the biomechanics of swallowing function in dysphagic Parkinson's patients. A combination of fiberoptic endoscopic evaluation of swallowing (FEES) and pharyngeal high-resolution manometry (HRM) will be employed to comprehensively evaluate the neuromuscular changes in swallowing.",[29,387],"Dysphagia",[387,389,169,390],"Expiratory muscle strength training","High-resolution pharyngeal manometry","2026-06-01",{"date":342,"type":46},{"date":152,"type":23},{"date":395,"type":23},"2028-05",{"name":397,"class":53},"University Hospital Muenster",{"id":399,"slug":4,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":62,"enrollmentInfo":404,"targetDuration":4,"studyType":24,"phases":406,"briefSummary":407,"conditions":408,"keywords":411,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":427},"100638891","NCT07630545","A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.","A Multi-part, Adaptive Phase 1, First Time in Human Study in Healthy Volunteers to Assess Safety, Tolerability and Pharmacokinetics (PK) Following Single Ascending Dose (SAD) and Multiple Ascending Doses (MAD) of MTX325, Including Option to Assess: a Single Dose in Elderly Participants; Multiple Doses in Patients With Parkinson's Disease (PD); Central Nervous System (CNS) Penetration, Biodistribution, and Biomarkers; and the Effect of Food on PK.","Inclusion Criteria:\n\nPart 1, 2 ,4\n\n1. Healthy male and female (Part 1-2 only) participant, aged ≥ 18 to ≤ 55 years.\n2. Female participant of childbearing potential (Part 1-2 only)\n3. Female participant of non-childbearing potential (Part 1-2 only).\n4. Female participant (Part 1-2 only) with a negative pregnancy test at Screening visit.\n5. Female participant of menopausal status (Part 1-2 only) confirmed by demonstrating at Screening that the serum level of the follicle stimulating hormone (FSH) falls within the respective pathology reference range.\n6. Male participant (and partner of childbearing potential) willing to use a highly effective method of contraception\n7. Participant with a body weight of at least 50.0 kg and body mass index (BMI) of 1832 kg\u002Fm2. BMI = body weight (kg) \u002F \\[height (m)\\]2.\n8. No clinically significant history of previous allergy \u002F sensitivity to MTX325 or any of the excipients contained within the IMP.\n9. No clinically significant abnormal test results for serum biochemistry, haematology, coagulation\n10. Participant with a negative urinary drugs of abuse (DOA) screen (including alcohol) test results, determined within 35 days (45 days Part 4 only) before first dose of IMP.\n11. Participant with negative human immunodeficiency virus (HIV), hepatitis B surface antigen \\[HbsAg\\]) and hepatitis C virus antibody (HCV Ab) test results at Screening.\n12. No clinically significant abnormalities in 12-lead electrocardiogram (ECG)\n13. No clinically significant abnormalities in vital signs\n14. Participant must be available to complete the study (including all follow-up visits).\n15. Participant must satisfy an Investigator about his\u002Fher fitness to participate in the study.\n16. Participant must provide written informed consent to participate in the study.\n17. Participants with a negative COVID-19 test on admission (if required).\n18. Part 4 only: Participant with normal MRI performed within 3 months of dosing, as judged by the investigator.\n\nPart 4 Only\n\n1. Participants who have had previous exposure to ionizing radiation from research studies\n2. Participant has any contraindication to arterial line insertion\n3. Inability to lie supine for up to 120 mins for PET procedures.\n4. Participant has any contra-indication to MRI as determined by screening procedures and MRI safety questionnaire\n5. Participant suffers from claustrophobia or needle phobia.\n6. Any history of allergy\u002Fatopy including drug-induced allergy or any history of severe cutaneous adverse reaction or other type 4\u002Fdelayed-type hypersensitivity.\n7. Current or previous history of eosinophilia with either unknown cause, or where known, the inciting factor is not removed or avoided.\n8. Previous history of Erythema Multiforme and\u002For identified current risk factor(s) for Erythema Part 3 Only\n\n1\\. Healthy male and female participant, ≥ 65 years of age. 2. Female participant of non-childbearing potential. 3. Female participant of menopausal status confirmed by demonstrating at Screening that the serum level of the follicle stimulating hormone (FSH) falls within the respective pathology reference range.\n\n4\\. Male participant (and partner of childbearing potential) willing to use a highly effective method of contraception 5. Participant with a body weight of at least 50.0 kg and BMI of 18-32 kg\u002Fm2. 6. No clinically significant history of previous allergy \u002F sensitivity to MTX325 or any of the excipients contained within the IMP.\n\n7\\. No clinically significant abnormal test results for serum biochemistry, haematology and\u002For urine analyses determined within 35 days before first dose of IMP.\n\n8\\. Participant with an estimated glomerular filtration rate (eGFR) calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation \\>60 mL\u002Fmin\u002F1.73 m2.\n\n9\\. Participant with a negative urinary drugs of abuse (DOA) 10. Participant with negative human immunodeficiency virus (HIV), hepatitis B surface antigen \\[HbsAg\\]) and hepatitis C virus antibody (HCV Ab) test results at Screening.\n\n11\\. No clinically significant abnormalities in 12-lead electrocardiogram (ECG) 12. No clinically significant abnormalities in vital signs 13. Participant must be available to complete the study (including all follow-up visits).\n\n14\\. Participant must satisfy an Investigator about his\u002Fher fitness to participate in the study.\n\n15\\. Participant must provide written informed consent to participate in the study.\n\n16\\. Participants with a negative COVID-19 test on admission. Part 5 Only\n\n1. Male and female participants aged ≥ 40 to ≤ 75 years.\n2. Male or female participants. Female participants of childbearing potential must be willing to use highly effective forms of contraception (refer to Section 9.7.1 for details on highly effective methods of contraception and definitions of women of childbearing potential and of fertile men):\n3. Body mass index (BMI) between 18 and 34.0 kg\u002Fm2, inclusive.\n4. If being treated with selective serotonin reuptake inhibitors (SSRIs) for anxiety\u002F depression, must be on a stable dose for 60 days prior to Day -1 and must remain on that dose for the remainder of the study.\n5. Must have had other causes of Parkinsonism excluded\n6. No clinically significant history of previous allergy\u002F sensitivity to MTX325 or any of the excipients contained within the IMP.\n7. Participant with a negative urinary drugs of abuse (DOA) screen (excluding alcohol).\n8. Participant with negative human immunodeficiency virus (HIV), hepatitis B surface antigen \\[HbsAg\\]) and hepatitis C virus antibody (HCV Ab) test results at Screening.\n9. No history of torsade de pointes or long QT syndrome and no heart failure, hypokalaemia, or any other additional cardiac risk factors if judged clinically significant in the opinion of the Investigator.\n10. No clinically significant abnormalities in vital signs during the screening period.\n11. Able to perform all protocol assessments and comply with the study visit schedule. 12. Able and willing to provide informed consent.\n\n13\\. Clinically established PD as per MDS Criteria\\[ 14. Absence of dementia as shown by a baseline Montreal Cognitive Assessment (MoCA®) Exclusion Criteria (Part 1, 2, 4)\n\n1. A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.\n2. Use of prescription or non-prescription drugs, excluding allowable drugs and contraception\n3. Reports having experienced suicidal ideation (Type 4 on 5 on the Columbia-Suicide Severity Rating Scale \\[C-SSRS©\\] him\u002Fherself or others - Part 2 only.\n4. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.\n5. A clinically significant history of drug or alcohol abuse (defined as the consumption of more than 14 units\n6. Inability to communicate well with the Investigators\n7. Participation (dosed) in a New Chemical Entity (NCE) clinical study within the previous 3 months or five half-lives\n8. Donation of 450 mL or more blood within the 3 months before the first dose of IMP.\n9. Vegans, vegetarians or other dietary restrictions (Part 1 food effect evaluation, only).\n10. Users of nicotine products\n11. Participants with an excessive habitual daily intake of caffeine\n12. Female participants who are pregnant, breastfeeding or lactating (Part 1-2 only).\n13. Participants with veins unsuitable for venepuncture and cannulation.\n14. Participants with recent COVID-19 infection without resolution of symptoms\n15. Participants who have received a COVID-19 vaccine injection\n\nPart 1 Treatment Period 2a (CSF sampling) Cohort(s) only:\n\n1. Participants who have criteria that would preclude a lumbar puncture (LP)\n2. Participant who has a history of clinically significant hypersensitivity to local anaesthesia\n3. Participant who has a history of clinically significant or major back pathology (lumbar) surgery\n\nPart 4 only:\n\n1. Participants who have had previous exposure to ionizing radiation from research studies, such that, in combination with the exposure from this study, their exposure will be \\>10 mSv for the previous 12 months.\n2. Participant has any contraindication to arterial line insertion\n3. Inability to lie supine for up to 120 mins for PET procedures.\n4. Participant has any contra-indication to MRI\n5. Participant suffers from claustrophobia or needle phobia.\n6. Any history of allergy\u002Fatopy\n7. Current or previous history of eosinophilia with either unknown cause, or where known, the inciting factor is not removed or avoided.\n8. Previous history of Erythema Multiforme and\u002For identified current risk factor(s) for Erythema Multiforme Part 3 Only\n\n1\\. A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.\n\n2\\. Evidence of febrile illness within 1 week of first dose of IMP. 3. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements or any medication known to prolong the QT\u002FQTc interval within 35 days or 5 half-lives 4. Evidence of clinically significant renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.\n\n5\\. History of torsade de pointes, heart failure, hypokalaemia, long QT syndrome or any other additional cardiac risk factors.\n\n6\\. A clinically significant history of drug or alcohol abuse 7. Participants with an excess habitual daily intake of caffeine 8. Inability to communicate well with the Investigators 9. Participation in a NCE clinical study within the previous 3 months or five half-lives 10. Donation of 450 mL or more blood within the 3 months before the first dose of IMP.\n\n11\\. Participants who have received a COVID-19 vaccine injection within 35 days prior to first dose of IMP.\n\n12\\. Users of nicotine products 13. Participants with veins unsuitable for venepuncture and cannulation. 14. Participants with recent COVID-19 infection with resolution of symptoms Part 5\n\n1. A clinically significant history of gastrointestinal disorders or any significant medical conditions that would be likely to influence IMP absorption, or evidence of clinically significant central nervous system, respiratory, cardiovascular or metabolic dysfunction or other significant medical conditions with potential to impact participant safety or hinder interpretation of study results.\n2. Clinically significant neurologic disorder other than PD, including history of stroke within 12 months of Screening, seizure within 5 years of Screening, or head trauma with loss of consciousness within 6 months of Screening.\n3. Those with known PD risk genes (per medical history).\n4. Reside in a nursing home or assisted care facility.\n5. No more than 2 PD related freezing episodes or falls in the past 6 months.\n6. Any condition that may predispose participant to complications or technical difficulty with lumbar puncture, in the opinion of the Investigator.\n7. Participant who has a history of clinically significant hypersensitivity to local anaesthesia, or its derivatives used during CSF collection or to any medication used to prepare the area of LP.\n8. Reports having experienced suicidal ideation (Type 4 on 5 on the Columbia-Suicide Severity Rating Scale \\[C-SSRS©\\]\n9. Participants should not be in receipt of any known MATE2k substrates\n10. Plan to receive or administration of rotigotine, catechol-o-methyltransferase (COMT) inhibitors (e.g., entacapone, tolcapone or opicapone), neuroleptics, venlafaxine, NMN, nicotinamide riboside or non-selective Monoamine oxidase \\[MAO\\] inhibitors within 7 days or 5 half-lives (whichever is longer) prior to first dose and during the study conduct.\n11. Clinically significant abnormal test results for serum biochemistry, haematology, coagulation and\u002For urine analyses as determined within 45 days before first dose of IMP.\n12. A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.\n13. Participant has any condition that, in the opinion of the investigator, is clinically significant and may put the participant at greater safety risk, influence response to study product, or interfere with study assessment.\n14. Inability to communicate well with the Investigators.\n15. Participation (dosed) in a NCE clinical study within the previous 3 months or five half lives\n16. Donation of 450 mL or more blood within the 3 months before the first dose of IMP.\n17. Female participants who are pregnant, breastfeeding or lactating.\n18. Clinically significant abnormalities in 12-lead electrocardiogram (ECG)\n19. Participants with recent COVID-19 infection without resolution of symptoms\n20. Participants who have received a COVID-19 vaccine injection from the Screening visit up to first dose of IMP\n21. A clinically significant history of drug or alcohol abuse within the past 2 years. Currently prescribed treatment for Parkinson's Disease symptoms.\n22. Any history of allergy\u002Fatopy including drug-induced allergy history of severe cutaneous adverse reaction or other type 4\u002Fdelayed-type hypersensitivity.\n23. Current or previous history of eosinophilia with either unknown cause, or where known, the inciting factor is not removed or avoided.\n24. Previous history of Erythema Multiforme and\u002For identified current risk factor(s) for Erythema Multiforme\n25. Participant has any contra-indication to PET or MRI as determined by screening procedures and PET and MRI safety questionnaires as conducted by the site.\n26. Clinically significant history of previous allergy\u002F sensitivity to \\[18F\\] FDG.\n27. Participants who have had previous exposure to ionizing radiation\n28. Chronic kidney disease defined as glomerular filtration rate (GFR) 1.5 × the upper limit of normal (ULN) or ALT or AST \\>3 × ULN or if participant has Child-Pugh Class C cirrhosis or equivalent severe hepatic impairment.\n29. Hepatic disease or altered liver function as defined by total bilirubin \\>1.5 × the upper limit of normal (ULN) or ALT or AST \\>3 × ULN or if participant has Child-Pugh Class C cirrhosis or equivalent severe hepatic impairment.\n30. Patients with uncontrolled type I or type II diabetes (insulin or non-insulin dependent).\n31. Current symptomatic Hay fever or any history of hay fever involving more than nose and eyes.",{"count":405,"type":23},106,[96],"The goal of this study is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease.",[29,409,410],"Mild to Moderate Parkinson's Disease","Early Stage Parkinson's Disease",[364,412,413,414,415,416,417,418],"MDS-UPDRS","CSF","Plasma","Biomarkers","Mild","Moderate","Hoehn and Yahr scale",{"date":322,"type":46},{"date":421,"type":46},"2023-11-30",{"date":423,"type":23},"2027-12-27",{"name":425,"class":426},"Mission Therapeutics","NETWORK",5,{"id":429,"slug":4,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":11,"sex":18,"minAge":434,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":24,"phases":437,"briefSummary":438,"conditions":439,"keywords":440,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":444,"completionDateStruct":445,"leadSponsor":447,"locationsCount":4},"100619088","NCT07340073","Coordinated Reset Deep Brain Stimulation for Parkinson's Disease","CR DBS PD","Inclusion Criteria:\n\n* Diagnosis of Idiopathic Parkinson's Disease\n* Minimum age of 21 years old\n* Will be or has been implanted with the Boston Scientific Vercise Genus Rechargeable DBS system\n\nExclusion Criteria:\n\n* History of musculoskeletal disorders that affect movement of the limbs\u002Fgait\n* Other significant neurological disorder\n* Significant psychiatric disorder\n* History of dementia or cognitive impairment that precludes them from getting DBS surgery or per study staff judgment, MacCAT-CR assessment does not deduce that the participant has capacity to consent\n* Other significant medical disorder that could impede study participation\n* Pregnant women","21 Years",{"count":436,"type":23},24,[96],"Deep brain stimulation (DBS) is a surgical implant procedure for the treatment of Parkinson's Disease (PD) utilizing medical devices approved by the FDA. A novel approach to current DBS approaches is called \"Coordinated Reset\" DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS (T-DBS) that uses continuous high amplitude and high frequency stimulation. This study will evaluate the safety and short-term efficacy of CR-DBS in PD. The results from this study will significantly advance the development of CR-DBS for the treatment of PD. Findings in this study will also provide the rationale for further development of this novel DBS approach for other neurological and psychiatric disorders.",[29,286],[441,169],"Deep Brain Simulation","2026-05-18",{"date":372,"type":46},{"date":201,"type":23},{"date":446,"type":23},"2031-07-01",{"name":448,"class":53},"University of Minnesota",{"id":450,"slug":4,"hasResults":11,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":11,"sex":18,"minAge":309,"maxAge":279,"enrollmentInfo":456,"targetDuration":4,"studyType":24,"phases":457,"briefSummary":458,"conditions":459,"keywords":460,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":54},"100629520","NCT07475741","Exergaming for Improving Upper Limb Functions in Parkinson's Disease","Exergaming With Physical Objects for Upper Limb Rehabilitation in Parkinson's Disease: Effects on Functional Outcome","Exergaming","Inclusion Criteria:\n\n* Early-stage Parkinson's Disease from I-III of Hoehn and Yahr scale\n* Cognitinve Assessment MMSE \\>= 24 Score\n* Able to communicate and understand the commands\n* Must be on regular use of Levodopa\u002Fcarbidopa\n\nExclusion Criteria:\n\n* Advanced stage IV or V\n* Patients with severe cognitive deficits.\n* History of suffering from other neurological or musculoskeletal conditions affecting hand use for the exercise\n* Not taking any medicine for systemic illness",{"count":94,"type":23},[26],"Parkinson's Disease commonly results in impaired hand dexterity, reducing a patient's ability to perform activities of daily living. While digital exergaming has been used to encourage physical activity and improve motor function, it often lacks real-world tactile engagement. Integrating physical objects into exergaming known as a phygital approach which may enhance sensorimotor learning and functional carryover. However, its impact on upper limb functional outcomes in PD remains underexplored.\n\nObjectives: To assess the effectiveness of exergaming with physical objects on functional outcomes of upper limb rehabilitation in individuals with Parkinson's Disease.\n\nMethodology: This randomized controlled pilot study will include 30 individuals with early-stage Parkinson's Disease, recruited through convenience sampling and randomly assigned to either a phygital exergaming group or a control group. Both groups will receive sessions over three monthd (3 sessions\u002Fweek, 30 minutes each). The phygital group will perform task-based exergaming using both physical objects and digital prompts, while the control group will use digital prompts alone. Functional outcomes will be assessed using the Box and Block Test (BBT), at baseline (day 1) and post intervention 12 weeks.\n\nStatistical Analysis: Data will be analyzed using SPSS version 25. Descriptive statistics like gender, stages of diseases etc. will be summarized and described as bar charts and percentages. Within-group differences will be assessed using paired t-tests or Wilcoxon signed-rank tests based on data normality. Between-group comparisons will be conducted using independent t-tests or Mann-Whitney U tests. A p-value of less than 0.05 will be considered statistically significant.",[122],[454,461,462,463],"Parkinson Disease","Physical Therapy","Upper Limb Rehabilitation","2026-05-14",{"date":466,"type":46},"2026-05-19",{"date":468,"type":46},"2026-02-20",{"date":470,"type":23},"2026-11",{"name":472,"class":53},"University of Health Sciences Lahore",{"id":474,"slug":4,"hasResults":11,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":17,"sex":18,"minAge":357,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":24,"phases":481,"briefSummary":482,"conditions":483,"keywords":485,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":497,"locationsCount":54},"100636576","NCT07567482","Exoskeleton-Assisted Mobility in Aging and in Parkinson's Disease","Exoskeleton-Assisted Mobility in Aging and in Parkinson's Disease: A Mixed-Methods Study of Effectiveness and Acceptability","Participants with Parkinson's disease\n\nInclusion Criteria:\n\n* Ability to walk for at least 30 minutes with or without minimal aid\n* Diagnosis of idiopathic Parkinson's disease\n* Hoehn and Yahr stage 1 to 4\n\nExclusion Criteria:\n\n* Height smaller than 152 cm\n* Severe vascular conditions of the lower limbs that may limit mobility or pose a risk.\n* Presence of any implantable or external life-sustaining medical device such as a pacemaker\n* Severe osteoporosis or high risk of fractures\n* Contra-indication to the required physical effort\n* Severe cognitive impairment (MoCA \\\u003C 21)\n* Presence of neurological disorders, lower-limb injuries, or other conditions interfering with mobility, other than Parkinson's disease.\n\nHealthy elderly participants without Parkinson's disease\n\nInclusion Criteria:\n\n* Ability to walk for at least 30 minutes with or without minimal aid\n* Age ≥ 65 years old\n\nExclusion Criteria:\n\n* Height smaller than 152 cm\n* Severe vascular conditions of the lower limbs that may limit mobility or pose a risk.\n* Presence of any implantable or external life-sustaining medical device such as a pacemaker\n* Severe osteoporosis or high risk of fractures\n* Contra-indication to the required physical effort\n* Severe cognitive impairment (MoCA \\\u003C 21)\n* Presence of neurological disorders, lower-limb injuries, or other conditions interfering with mobility",{"count":480,"type":23},26,[26],"This study will evaluate whether a wearable robotic exoskeleton can improve mobility, balance, and walking in healthy older adults and in individuals living with Parkinson's disease, populations at high risk of falls and mobility limitations. Participants will attend two laboratory sessions. The first session includes clinical assessments, fitting and familiarization with the exoskeleton, and interviews to explore user perceptions. The second session involves performing functional mobility tasks (e.g., walking, standing, turning) with and without the exoskeleton and under different assistance levels, while movement is measured using wearable sensors.\n\nThe study will assess the immediate effects of the exoskeleton on mobility, compare assistance levels, identify which participants benefit most, and explore user experience and acceptability. Findings will help inform the development and implementation of assistive technologies to support mobility in healthy aging and in individuals with Parkinson's disease.",[29,484],"Healthy Aging",[486,487,36,169,488,489,490],"Exoskeleton","Mobility","Walking","Balance","Risk of falls","2026-05-11",{"date":493,"type":46},"2026-05-13",{"date":495,"type":46},"2026-04-30",{"date":470,"type":23},{"name":498,"class":499},"Centre intégré de santé et de services sociaux de l'Outaouais","OTHER_GOV",{"id":501,"slug":4,"hasResults":11,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":17,"sex":18,"minAge":506,"maxAge":279,"enrollmentInfo":507,"targetDuration":4,"studyType":508,"phases":4,"briefSummary":509,"conditions":510,"keywords":512,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":86},"100636689","NCT07568951","Impact of Force Control of Hip Abductor Muscles in Healthy Adults and Individuals With Parkinson's Disease","Impact of Force Control of Hip Abductor Muscles on Postural Control in Middle-aged and Older Adults and Individuals With Parkinson's Disease","Healthy people\n\nInclusion Criteria:\n\n* 20 to 39 years (young), 40 to 59 years (young), and 60-85 years (old)\n* generally in good health\n* able to walk 10 m independently\n* able to follow all instructions\n\nExclusion Criteria:\n\n* neurologic, psychiatric, immune, integumentary, and musculoskeletal diseases or disorders which might influence this study\n* any pain over the lower extremities\n* uncontrolled cardiovascular diseases\n* unable to provide informed consent.\n\nPD\n\nInclusion Criteria:\n\n* clinical diagnosis of idiopathic PD\n* Hoehn and Yahr stages 1 to 3\n* stable anti-PD medications\n* able to walk 10 m independently\n* able to follow all instructions\n\nExclusion Criteria:\n\n* psychiatric, immune, integumentary, and musculoskeletal diseases or disorders which might influence this study\n* neurological conditions other than PD\n* any pain over the lower extremities\n* uncontrolled cardiovascular diseases\n* unable to provide informed consent.","20 Years",{"count":22,"type":23},"OBSERVATIONAL","Both aging and Parkinson's disease (PD) negatively affect postural control and increase the risk of falls, with frontal plane balance being particularly challenging for these populations. While previous studies have mainly focused on sagittal plane balance, the contribution of hip abductor muscles remains unclear, especially regarding their force production and control abilities. Therefore, this study aims to investigate hip abductor muscle force production and force control, and to examine whether these factors are associated with postural control, gait, and balance performance in individuals across different ages and those with PD.",[511,29],"Aging",[513,364,514,515,516,517],"Old","muscle force","force steadiness","balance","gait performance","2026-05-04",{"date":520,"type":46},"2026-05-08",{"date":522,"type":46},"2023-08-01",{"date":524,"type":23},"2029-07-31",{"name":526,"class":53},"Chang Gung Memorial Hospital",{"id":528,"slug":4,"hasResults":11,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":24,"phases":534,"briefSummary":535,"conditions":536,"keywords":538,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":54},"100640749","NCT07574164","Closed-loop TMS for Tremor","Transcranial Magnetic Stimulation for the Treatment of Tremo","Inclusion Criteria:\n\n* having either essential tremor or Parkinson's disease\n\nExclusion Criteria:\n\n* contraindications to brain stimulation",{"count":118,"type":23},[26],"This study investigates the potential of phase-locked transcranial magnetic stimulation (TMS) as a non-invasive intervention for tremor in patients with Essential Tremor (ET) and Parkinson's Disease (PD). Tremor is a prevalent symptom that significantly impacts physical function and social participation. ET affects approximately 1% of the global population and worsens with age, while PD tremor is often less responsive to conventional dopaminergic therapy. Current treatments, including oral medications (propranolol, primidone), anticholinergics, and deep brain stimulation (DBS), are either limited by efficacy, side effects, or invasiveness. These challenges highlight the need for alternative, less invasive therapeutic options.\n\nThe rationale for the study is based on the principle of phase-dependent neural modulation. Just as a swing's amplitude can be increased or decreased depending on when it is pushed, neural oscillations underlying tremor can theoretically be suppressed by precisely timed stimulation. Previous studies have shown that TMS over the motor cortex at tremor frequency (\\~5 Hz) produces modest improvements in PD rest tremor. This study aims to enhance these effects by targeting amplitude-suppressing phases in the tremor cycle, potentially leading to greater and cumulative tremor reduction.\n\nThe study has two components:\n\nStudy 1 (Primary Objective): Determine whether phase-locked TMS can acutely reduce tremor. Participants (20 ET, 20 PD) will undergo two visits where tremor is recorded via inertial measurement units (IMUs) and surface EMG. TMS will be delivered over the motor cortex at or below active motor threshold, synchronized to the participant's tremor phase. The primary outcome is the change in tremor power during stimulation compared to no stimulation, measured objectively via IMU signals.\n\nStudy 2 (Secondary Objective): Examine whether stimulation at the maximal tremor-suppressing phase, identified in Study 1, produces a larger reduction in tremor amplitude than stimulation at the minimal suppressing phase or sham stimulation. This will involve three additional sessions per participant, randomized for order, with outcomes assessed via IMU tremor power and participant-reported measures including the Quality of Life in Essential Tremor Questionnaire (QUEST), TETRAS, and Unified Parkinson's Disease Rating Scale (UPDRS).\n\nStudy Design and Procedures: The design is a within-subject crossover. Participants may withhold tremor medications during visits to reduce confounding effects. EMG electrodes and IMU sensors will record tremor, while a figure-of-eight TMS coil will deliver phase-locked pulses. Phase-specific stimulation trains are applied for 3 seconds at intervals, with randomized order across multiple blocks. Study sessions last under two hours, including setup and post-stimulation recordings.\n\nParticipants are recruited via self-referral or through DeNDRoN, screened for eligibility, and provide informed consent. Inclusion criteria require symptomatic ET or PD tremor, age ≥18, and ability to consent. Exclusion criteria include epilepsy, psychiatric illness, metal implants, pacemakers, or other conditions contraindicating TMS. Participants may withdraw at any time without penalty.\n\nSafety Measures: TMS and IMU recordings are low-risk, with potential minor effects including scalp tapping sensations, muscle twitches, or mild headaches, which are managed through monitoring and coil adjustment. Serious adverse events are defined, and procedures for reporting and auditing are established in accordance with UK regulations and Good Clinical Practice.\n\nData Analysis: Tremor power will be quantified from IMU recordings using spectral analysis. Statistical comparisons between stimulation conditions and baseline will be conducted using paired t-tests or Wilcoxon tests. The study will employ validated software for randomization and analysis (SPSS, Matlab). Data will be pseudo-anonymized, securely stored, and archived for long-term research use.\n\nEthical Considerations: The study follows the Declaration of Helsinki, Good Clinical Practice, and institutional approvals. Participants' privacy and data protection are ensured under GDPR standards. There are no commercial conflicts of interest, and participants are reimbursed for travel expenses.\n\nIn summary, this research aims to evaluate the efficacy of phase-locked TMS as a non-invasive, targeted interventionfor tremor in ET and PD. By systematically stimulating the motor cortex at tremor-specific phases, the study seeks to establish a foundation for future minimally invasive treatments that could complement or replace existing pharmacological and surgical options.",[537,29],"Essential Tremor",[539],"tremor","2026-05-01",{"date":542,"type":46},"2026-05-07",{"date":544,"type":46},"2024-01-01",{"date":546,"type":23},"2028-01-01",{"name":548,"class":53},"University of Oxford",{"id":550,"slug":4,"hasResults":11,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":554,"eligibilityCriteria":555,"healthyVolunteers":11,"sex":18,"minAge":357,"maxAge":116,"enrollmentInfo":556,"targetDuration":4,"studyType":24,"phases":558,"briefSummary":559,"conditions":560,"keywords":561,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":54},"100597862","NCT07064005","Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.","Brain Glutathione (GSH) Enrichment Through Gamma-glutamylcysteine (GGC) Supplementation in Early Parkinson's Disease Patients for Reduction of Extrapyramidal Motor Disturbances and Halting Cognition Decline: A Pilot Trial","PDGSH","Inclusion Criteria:\n\n* Confirmed Parkinson's Disease diagnosis.\n* Montreal Cognitive Assessment (MoCA) greater than or equal to 26.\n* Age (50 to 80 years of age).\n* Ability to read and write in English.\n\nExclusion Criteria:\n\n* Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments in the eyes, skin, or body.\n* Subjects with claustrophobia.\n* Patients with a clinical diagnosis of Parkinson's disease dementia or dementia with Lewy bodies.\n* Subjects with a history of cancer.\n* Subjects with active psychosis or delirium.\n* Subjects with chronic kidney (creatinine \\> 1.5mg\u002FdL) or liver disease (AST ≥ 1.5 ULN; ALT ≥ 1.5 ULN) within 30 days prior to enrolment.\n* Subjects on antioxidant therapy (ashwagandha, gingko biloba or N-acetylcysteine) or illicit drug abuse\u002Fdependence (cocaine, heroin, marijuana, or fentanyl).\n* Subjects with previous traumatic head injury.",{"count":557,"type":23},12,[96],"This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate:\n\n1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation.\n2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation\n3. To study impact of GGC on gut health on the PD patients.",[122],[562,563,564,565,566,567,568,569],"Blood","Brain","MR Spectroscopy","GGC","Glutathione","Parkinsons disease","Oxidative stress","Brain Iron",{"date":518,"type":46},{"date":572,"type":46},"2026-03-23",{"date":574,"type":23},"2027-11-27",{"name":576,"class":53},"Pravat Mandal",{"id":578,"slug":4,"hasResults":11,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":582,"eligibilityCriteria":583,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":24,"phases":586,"briefSummary":587,"conditions":588,"keywords":590,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":54},"100592449","NCT06993571","Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor","Closed-loop Phase-adaptive Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Activity in the Cerebello-thalamo-cortical Network to Reduce Parkinson's Disease Tremor","tACS_PD_TR","Inclusion Criteria:\n\n* Clinical diagnosis of Parkinson's disease based on UK Brain Bank criteria\n* Patient exhibiting moderate to severe hand tremor\n* Provision written informed consent by the patient\n\nExclusion Criteria:\n\n* History of other neurological disorders such as vascular malformations, ischemic or haemorrhagic stroke, cerebral neoplasia, epilepsy, or major psychiatric illness\n* Existence of heart pacemaker or metal implants in the body\n* Pregnancy",{"count":585,"type":23},10,[26],"Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by different motor symptoms, including tremor, which is particularly difficult to manage. Common treatments, such as dopaminergic therapy, can have limitations in efficacy. Recent advancements in non-invasive brain stimulation, specifically phase-adaptive transcranial alternating current stimulation (tACS), offer a promising approach to reduce PD tremor. In the current project, a newly developed closed-loop system delivers precisely synchronized cerebellar tACS by aligning stimulation with the intrinsic hand tremor signal. The study will assess the efficacy of this novel approach to reduce hand tremor in PD patients.",[29,589],"Tremor",[364,591,592,593,594,595,596],"Hand tremor","Transcranial alternating current stimulation","Non-invasive brain stimulation","Closed-loop stimulation","Phase-adaptive stimulation","Tremor entrainment","2026-04-28",{"date":518,"type":46},{"date":600,"type":46},"2025-04-16",{"date":602,"type":23},"2026-12-31",{"name":604,"class":53},"Universitätsklinikum Hamburg-Eppendorf",{"id":606,"slug":4,"hasResults":11,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":24,"phases":614,"briefSummary":615,"conditions":616,"keywords":619,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":629,"completionDateStruct":630,"leadSponsor":632,"locationsCount":86},"100629446","NCT07474779","Understanding Alpha-Synuclein Spread in Parkinson's Disease Through Blood Biomarkers and Neuroimaging","From Genes to Virtual Brain: Defining the Pathogenic Mechanisms Promoting Alfa-synuclein Seeding and Spreading in Parkinson's Disease.","SYNchronPD","Inclusion criteria for Parkinson's disease cohorts (GBA-PD and nonGBA-PD):\n\n* Diagnosis of PD according to MDS-PD criteria and, for the GBA-PD group, presence of heterozygous GBA mutations (with a balanced distribution of severe, risk, mild, and complex variants);\n* Disease duration between 3 and 7 years;\n* Disease stage according to Hoehn \\& Yahr ≤ 3;\n* Absence of mutations in other known genes associated with PD susceptibility;\n* Age \\> 18 Years;\n* Ability to understand and voluntarily sign informed consent and to comply with study procedures.\n\nExclusion criteria for Parkinson's disease cohorts:\n\n* Diagnosis of atypical and\u002For secondary parkinsonism;\n* Diagnosis of dementia according to DSM-5 criteria;\n* Presence of other neurological disorders and\u002For essential tremor;\n* Presence of systemic inflammatory or infectious diseases, autoimmune diseases, or malignant tumors at the time of enrollment.\n\nInclusion criteria for unaffected subjects (GBA-nonPD and nonGBA-nonPD):\n\n* Age \\> 18 Years;\n* Ability to understand and voluntarily sign informed consent and to comply with study procedures;\n* No diagnosis of PD or other neurological disorders;\n* Presence of a heterozygous GBA mutation for the GBA-nonPD group and absence of such mutation for control subjects (nonGBA-nonPD);\n* Absence of mutations in other known genes associated with PD susceptibility.\n\nExclusion criteria for unaffected subjects (GBA-nonPD and nonGBA-nonPD):\n\n* Presence of systemic inflammatory or infectious diseases, autoimmune diseases, or malignant tumors at the time of enrollment;\n* Diagnosis of atypical and\u002For secondary parkinsonism;\n* Diagnosis of dementia according to DSM-5 criteria.\n\nInclusion criteria for subjects with idiopathic REM Sleep Behavior Disorder (GBA-iRBD and nonGBA-iRBD):\n\n* Diagnosis of idiopathic REM Sleep Behavior Disorder according to ICSD-3;\n* Age \\> 18 Years;\n* Ability to understand and voluntarily sign informed consent and to comply with study procedures;\n* No diagnosis of PD or other neurological disorders;\n* Presence of a heterozygous GBA mutation for the GBA-iRBD group and absence of such mutation for the nonGBA-iRBD group;\n* Absence of mutations in other known genes associated with PD susceptibility.\n\nExclusion criteria for subjects with idiopathic REM Sleep Behavior Disorder (GBA-iRBD and nonGBA-iRBD):\n\n* Presence of systemic inflammatory or infectious diseases, autoimmune diseases, or malignant tumors at the time of enrollment;\n* Diagnosis of atypical and\u002For secondary parkinsonism;\n* Diagnosis of dementia according to DSM-5 criteria.",{"count":613,"type":23},160,[26],"The project aims to investigate how abnormal accumulation of alpha synuclein and its interaction with tau influence brain function across the Parkinson's disease (PD) spectrum, with particular focus on individuals carrying GBA1 mutations. This interventional, monocentric, cross sectional study includes patients with PD, individuals with idiopathic REM sleep behavior disorder, and participants without PD.\n\nAll enrolled subjects will undergo clinical and neuropsychological assessments, blood based biomarker analyses related to neurodegeneration, synaptic and mitochondrial function, and multimodal brain MRI to evaluate brain structure, white matter integrity, and functional connectivity.\n\nThe study aims to:\n\n* characterize the relationship between alpha synuclein\u002Ftau pathology and synaptic mitochondrial dysfunction;\n* identify biomarker and connectivity signatures across disease stages and genetic backgrounds;\n* integrate preclinical, clinical, biological, and imaging data to support the development of mechanistic models of alpha synuclein propagation.\n\nIn parallel, preclinical studies in GBA PD mouse models and wild type mice will be used to investigate how changes in PD-related pathology (alpha-synuclein and tau) relates to behavior, brain imaging alterations and mitochondrial, axonal and synaptic damage. Animal model will also aid the validation of a new PET tracer that targets alpha synuclein (i.e., \\[¹⁸F\\]Syntacasyn).\n\nTogether, human and preclinical studies are designed to provide a translational framework integrating molecular changes with brain network alterations and clinical heterogeneity in PD.",[29,617,618],"GBA1 Parkinson Disease","REM Sleep Behavior Disorder (iRBD)",[620,621,622,623,624,625,626],"GBA1 carriers","Brain Connectivity","Virtual Brain","Extracellular vesicles","Mitochondrial Dysfunction","Mice Models","Translational Science","2026-04-27",{"date":540,"type":46},{"date":491,"type":23},{"date":631,"type":23},"2029-02",{"name":633,"class":53},"University of Pavia",{"id":635,"slug":4,"hasResults":11,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":4,"eligibilityCriteria":639,"healthyVolunteers":11,"sex":18,"minAge":434,"maxAge":4,"enrollmentInfo":640,"targetDuration":4,"studyType":24,"phases":642,"briefSummary":643,"conditions":644,"keywords":645,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":649,"completionDateStruct":650,"leadSponsor":652,"locationsCount":54},"100609507","NCT07215481","Automated Image-Guided Programming of Deep Brain Stimulation (DBS) for Parkinson's Disease","Quantitative Digitography to Evaluate the Efficacy of Image Guided Algorithmic DBS Programming","Inclusion Criteria:\n\n* Diagnosis of Parkinson's disease (PD)\n* Newly implanted or soon to be implanted with deep brain stimulation (Boston Scientific device)\n* Willingness to withdraw from clinical medication regimen when necessary for research visits\n\nExclusion Criteria:\n\n* Dementia\n* Unable or unwilling to come OFF DBS for a short period of time",{"count":641,"type":23},15,[26],"The goal of this clinical trial is to evaluate an automated deep brain stimulation (DBS) algorithm developed by Boston Scientific called Illumina 3D for motor symptoms in Parkinson's disease (PD). The main question it aims to answer is: Is this new automated algorithm effective for treating motor symptoms of PD. Fifteen participants are anticipated to be enrolled.\n\nParticipants are individuals who recently were implanted with DBS in the subthalamic nucleus as part of their regular clinical treatment and are scheduled to have their DBS turned ON for the first time. In addition to their regular clinical visit when their DBS is turned ON by their clinician, participants are tested on DBS settings determined by Illumina 3D (an automated algorithm). Participants are tested on these different settings across different motor tasks, including walking and finger tapping, as well as answering questionnaires. The experiment is expected to last 1 or 2 days; this is not a longitudinal or long-term trial. Participants return to their usual DBS settings once they leave the clinic.",[29],[646,289,288,364],"deep brain stimulation","2026-04-22",{"date":627,"type":46},{"date":152,"type":23},{"date":651,"type":23},"2027-12",{"name":653,"class":53},"Stanford University",""]